Roche has reported a phase 3 win for sefaxersen, an experimental kidney disease treatment developed with Ionis. The positive result clears the way for the company to open talks with regulators about how to pursue approval.
According to Fierce Biotech, the candidate is viewed as a potential blockbuster. The win intensifies a rivalry with Novartis, which is also targeting the kidney disease market. Roche's progress suggests the two drugmakers are heading toward a direct commercial contest.
Regulatory discussions will be the next key step. The outcome will help determine how quickly sefaxersen can reach patients and how the competitive dynamics in the kidney disease space evolve.